767 related articles for article (PubMed ID: 12728784)
1. [Breakthrough in breast cancer chemoprevention].
Kahán Z; Thurzó L
Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
[TBL] [Abstract][Full Text] [Related]
2. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
3. Progress in chemoprevention of breast cancer.
Serrano D; Perego E; Costa A; Decensi A
Crit Rev Oncol Hematol; 2004 Feb; 49(2):109-17. PubMed ID: 15012972
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
5. 14. Breast cancer prevention.
Salih AK; Fentiman IS
Int J Clin Pract; 2002 May; 56(4):267-71. PubMed ID: 12074209
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
8. The potential for aromatase inhibition in breast cancer prevention.
Lønning PE; Kragh LE; Erikstein B; Hagen A; Risberg T; Schlichting E; Geisler J
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4423s-4428s; discussion 4411s-4412s. PubMed ID: 11916235
[TBL] [Abstract][Full Text] [Related]
9. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of breast cancer.
Castrellon AB; Glück S
Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
[TBL] [Abstract][Full Text] [Related]
12. Risk-reducing strategies for breast cancer--a review of recent literature.
Mokbel K
Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
[TBL] [Abstract][Full Text] [Related]
13. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Kondo M; Hoshi SL; Toi M
Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
[TBL] [Abstract][Full Text] [Related]
15. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
16. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
Ricart JJ
Medicina (B Aires); 2004; 64(1):66-72. PubMed ID: 15034961
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention for breast cancer.
Bozovic-Spasojevic I; Azambuja E; McCaskill-Stevens W; Dinh P; Cardoso F
Cancer Treat Rev; 2012 Aug; 38(5):329-39. PubMed ID: 21856081
[TBL] [Abstract][Full Text] [Related]
18. Update on breast cancer prevention.
Rastogi P; Vogel VG
Oncology (Williston Park); 2003 Jun; 17(6):799-805; discussion 808-10, 813. PubMed ID: 12846124
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract][Full Text] [Related]
20. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
Jordan VC
Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
